Suppr超能文献

对多重耐药菌株具有增强抗葡萄球菌活性的异噻唑并喹诺酮类:6、7和8位结构修饰的影响

Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.

作者信息

Wang Qiuping, Lucien Edlaine, Hashimoto Akihiro, Pais Godwin C G, Nelson David M, Song Yongsheng, Thanassi Jane A, Marlor Christopher W, Thoma Christy L, Cheng Jijun, Podos Steven D, Ou Yangsi, Deshpande Milind, Pucci Michael J, Buechter Douglas D, Bradbury Barton J, Wiles Jason A

机构信息

Achillion Pharmaceuticals, Inc., 300 George Street, New Haven, Connecticut 06511, USA.

出版信息

J Med Chem. 2007 Jan 25;50(2):199-210. doi: 10.1021/jm060844e.

Abstract

We describe the biological evaluation of isothiazoloquinolones (ITQs) having structural modifications at the 6-, 7-, and 8-positions. Addition of a methoxy substituent to C-8 effected an increase in antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and a decrease in cytotoxic activity against Hep2 cells. Removal of fluorine from C-6 or replacement of the C-8 carbon with a nitrogen compromised anti-MRSA activity. When the groups attached at C-7 were compared, the anti-MRSA activity decreased in the order 6-isoquinolinyl > 4-pyridinyl > 5-dihydroisoindolyl > 6-tetrahydroisoquinolinyl. The compound with the most desirable in vitro biological profile was 9-cyclopropyl-6-fluoro-8-methoxy-7-(2-methylpyridin-4-yl)-9H-isothiazolo[5,4-b]quinoline-3,4-dione (7g). This ITQ demonstrated (i) strong in vitro anti-MRSA activity (MIC90 = 0.5 microg/mL), (ii) strong inhibitory activities against S. aureus DNA gyrase and topoisomerase IV, with weak activity against human topoisomerase II, (iii) weak cytotoxic activities against three cell lines, and (iv) efficacy in an in vivo murine thigh model of infection employing MRSA.

摘要

我们描述了在6、7和8位具有结构修饰的异噻唑并喹啉酮(ITQ)的生物学评价。在C-8位添加甲氧基可提高对耐甲氧西林金黄色葡萄球菌(MRSA)的抗菌活性,并降低对Hep2细胞的细胞毒性活性。从C-6位去除氟或用氮取代C-8位的碳会损害抗MRSA活性。比较连接在C-7位的基团时,抗MRSA活性按6-异喹啉基>4-吡啶基>5-二氢异吲哚基>6-四氢异喹啉基的顺序降低。具有最理想体外生物学特性的化合物是9-环丙基-6-氟-8-甲氧基-7-(2-甲基吡啶-4-基)-9H-异噻唑并[5,4-b]喹啉-3,4-二酮(7g)。这种ITQ表现出:(i)强体外抗MRSA活性(MIC90 = 0.5微克/毫升),(ii)对金黄色葡萄球菌DNA回旋酶和拓扑异构酶IV有强抑制活性,对人拓扑异构酶II活性较弱,(iii)对三种细胞系细胞毒性活性较弱,以及(iv)在使用MRSA的体内小鼠大腿感染模型中有疗效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验